[
  {
    "ts": null,
    "headline": "Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market",
    "summary": "Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a \"right to win\" on the obesity drugs that have become a major market.",
    "url": "https://finnhub.io/api/news?id=3f49f30335bfffdeb3ba47e6c365e5d5c93d007fb665c9c040a64b552344b322",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763054096,
      "headline": "Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market",
      "id": 137470176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a \"right to win\" on the obesity drugs that have become a major market.",
      "url": "https://finnhub.io/api/news?id=3f49f30335bfffdeb3ba47e6c365e5d5c93d007fb665c9c040a64b552344b322"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call",
    "summary": "Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above Wall Street expectations for both revenue and earnings. Management attributed the outperformance to rigorous cost discipline, with CEO Stéphane Bancel noting a 34% reduction in combined cost of sales, R&D, and SG&A compared to last year. The company also cited strong market uptake of its new COVID vaccine, mNEXSPIKE, and the impact of ongoing productivity initiatives. CFO Jam",
    "url": "https://finnhub.io/api/news?id=bfa0f13230e4a6d66076185b42836e880f1af75f41391fa77302e29e99e47c7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763012381,
      "headline": "5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call",
      "id": 137468555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above Wall Street expectations for both revenue and earnings. Management attributed the outperformance to rigorous cost discipline, with CEO Stéphane Bancel noting a 34% reduction in combined cost of sales, R&D, and SG&A compared to last year. The company also cited strong market uptake of its new COVID vaccine, mNEXSPIKE, and the impact of ongoing productivity initiatives. CFO Jam",
      "url": "https://finnhub.io/api/news?id=bfa0f13230e4a6d66076185b42836e880f1af75f41391fa77302e29e99e47c7a"
    }
  },
  {
    "ts": null,
    "headline": "3 Small-Cap Stocks with Warning Signs",
    "summary": "Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.",
    "url": "https://finnhub.io/api/news?id=f6eb0cd84205f6a58a52eaab10c1ecc7ab041724e812686215768511d67ac469",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763008737,
      "headline": "3 Small-Cap Stocks with Warning Signs",
      "id": 137469438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.",
      "url": "https://finnhub.io/api/news?id=f6eb0cd84205f6a58a52eaab10c1ecc7ab041724e812686215768511d67ac469"
    }
  }
]